Formaldehyde Dehydrogenase - Pipeline Review, H2 2019

Formaldehyde Dehydrogenase - Pipeline Review, H2 2019

Summary

According to the recently published report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019'; Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) pipeline Target constitutes close to 5 molecules.

Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Formaldehyde dehydrogenase (FDH) is a zinc-containing metalloenzyme that catalyzes the oxidation of formaldehyde to formate. Formaldehyde dehydrogenase decomposes S-nitrosoglutathione and indirectly regulates the level of cellular protein S-nitrosation. It plays important role in respiratory diseases such as asthma.

The report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019' outlays comprehensive information on the Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 5 respectively. Report covers products from therapy areas Respiratory, Cardiovascular, Immunology, Gastrointestinal and Metabolic Disorders which include indications Inflammation, Crohn's Disease (Regional Enteritis), Diabetes, Idiopathic Pulmonary Fibrosis, Stroke, Asthma, Cardiac Arrest, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (Heart Failure), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Non-Alcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis.

Scope

• The report provides a snapshot of the global therapeutic landscape for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)
• The report reviews Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics and enlists all their major and minor projects
• The report assesses Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope